An open label, single-dose, single-period study designed to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]-CORT125329 in healthy male subjects
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Zavacorilant (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Acronyms QSC206122
- Sponsors Corcept Therapeutics
Most Recent Events
- 28 Oct 2022 New trial record
- 27 Oct 2022 Status changed from not yet recruiting to recruiting.